Bruker Daltonics Launches Worldwide CLINPROT FORUM as a Protein/Peptide Biomarker Customer Support Network.

WASHINGTON -- At the 97th American Association for Cancer Research (AACR) Annual Meeting 2006, Bruker Daltonics today announces the launch of its CLINPROT FORUM for the support of customers in protein/peptide biomarker discovery and validation, as well as in clinical and applied proteomics. The CLINPROT(TM) product line (for research use only) covers various aspects of biomarker analysis with special emphasis on body-fluid and tissue profiling, MALDI molecular imaging, and protein/peptide-based micro-organism identification and classification. The CLINPROT solution includes magnetic bead sample pre-fractionation, MALDI-TOF analysis and streamlined bioinformatics and visualization tools.

The goal of the newly created international CLINPROT FORUM is to establish efficient networking amongst a rapidly growing worldwide community of CLINPROT users. This discussion forum covers various aspects of clinical proteomics, such as biofluid profiling and validation, biomarker identification, the MALDI Molecular Imager(TM) and the MALDI BioTyper(TM) for microorganism identification. The CLINPROT FORUM facilitates efficient information exchange and should stimulate the formation of research collaborations between different laboratories. Special discussion threads include topics like sample preparation, standardization, biomarker identification and bioinformatics methods. A CLINPROT FORUM download site provides the latest protocols for sample preparation with CLINPROT magnetic beads, as well as recent publication lists and application notes.

The CLINPROT FORUM, which is moderated by expert Bruker application scientists, is available for all Bruker Daltonics customers and can be reached under http://clinprot.bdal.de.

Dr. Nils von Neuhoff, Head of Molecular Genetic Diagnostics, Institute of Cell and Molecular Pathology at Hannover Medical School, Germany, commented: "Researchers in the field of proteomic biomarker analysis and profiling of body fluids need to cover knowledge in diverse areas, like standardization of sample preparation, mass spectrometry and sophisticated mathematical approaches for pattern matching. Last but not least, they need to have a deep clinical knowledge concerning useful definitions of matching sample cohorts, anamnesis of patients and therapy decisions. For all those interdisciplinary tasks, it is very helpful to have the backup of a network of leading scientists from all over the world with special knowledge in different sub-disciplines of clinical proteomics. The collection and distribution of the latest protocols supplied in CLINPROT FORUM is of additional benefit for all participants."

Dr. Wolfgang Pusch, Assistant Vice President for Clinical Research Solutions at Bruker Daltonics, explained: "In our CLINPROT customer group, we have deep and diverse knowledge about biomarker analysis by means of mass spectrometry, but it is distributed all over the world from Asia/Pacific to Europe to the Americas. Some of these experts do not have the chance to meet personally and exchange information face-to-face on a regular basis. Our new CLINPROT FORUM will facilitate networking between our customers, and moreover accelerate the dissemination of best practices and protocols, of relevant recent literature and publications, as well as of timely CLINPROT method updates."

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts, is the parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.